With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...

Today on Living Oklahoma we were joined by Rebecca Jones.She spoke to Matt Stafford about here journey with Alzheimer's and ...

Eisai has slashed 2027 sales projections for its Biogen-partnered Alzheimer’s treatment Leqembi by roughly half.

McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...

Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's ...

In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Four ...

In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...

Lenvima sales are up solidly by around 10%, with Leqembi launching into its commercial phase now at 29.4 billion JPY cumulatively. Sequential performance has been solid. With a 42.5 billion JPY ...

According to Eisai's simulation, Leqembi sales will reach JPY 250 to 280 billion for their financial year (FY) 2027, which ends in March 2028. Eisai's presentation can be found on https://www ...